¿Nos visitas desde USA? Entra a tu página Rankia.us.

Novavax (NVAX): Un Nuevo Comienzo

4501 respuestas
  1. Kochikame

    Re: Novavax (NVAX): Un Nuevo Comienzo

    MODO VACACIONES:

    Estoy de vacaciones y voy controlando el valor a traves de ST, a ver que pasa hoy, os deseo surte a todos (los largos claro :)

    Si hay pump and dump, me voy hechndo leches...

  2. framus_morrigan

    Re: Novavax (NVAX): Un Nuevo Comienzo

     

    Novavax EPS in-line, beats on revenue

    Aug. 8, 2017 4:09 PM ET|By:  Gaurav Batavia, SA News Editor 

    Novavax (NASDAQ: NVAX): Q2 EPS of -$0.16 in-line.

    Revenue of $6.73M (+169.2% Y/Y) beats by $0.43M.

     

    http://ir.novavax.com/news-releases/news-release-details/novavax-reports-second-quarter-2017-financial-results

    A destacar

    Novavax’ nanoparticle flu vaccine demonstrates superior immunogenicity and protection compared to market leader in preclinical challenge studies. In head-to-head comparison studies against Fluzone® High-Dose, Novavax’ nanoparticle influenza vaccine with our proprietary Matrix-M™ adjuvant (NanoFlu) demonstrated significantly stronger and broader immune responses against matched and unmatched influenza strains, including a series of “drifted” strains evolved over more than a decade of influenza seasons. NanoFlu was also protective in an established challenge model against both a matched and a ten-year old unmatched strain. Further details will be published in the near future in a peer-reviewed journal and presented at scientific conferences.

    • Initiation of a Phase 1/2 clinical trial of the Company’s NanoFlu vaccine candidate in a head-to-head comparison to Fluzone High-Dose. Data from this trial should be available in the fourth quarter of 2017.

     

    y $187.3 million in cash, mejor de lo que esperaba ...

    Sobre la dilucion ATM

    During the six months ended June 30, 2017, the Company sold 18.0 million shares of common stock between February 28, 2017 and June 27, 2017 (the “Trading Period”) resulting in $22.7 million in net proceeds (this amount excludes $0.3 million received in the third quarter of 2017 for shares traded in late June 2017). The weighted average sales price achieved during the Trading Period was $1.31 per share. F rom July 1, 2017 through August 4, 2017, the Company sold an additional 3.9 million shares of common stock resulting in $5.7 million in net proceeds. Through August 4, 2017, the Company sold aggregate gross proceeds of $29.4 million of common stock of the $75 million total amount available under the Sales Agreement.

     

    Alrededor del 40% de la dilucion ATM ya ha sido ejecutada


Brokers destacados

17816 ig
12075 cmc markets 1493202387
18078 ibroker
18053 degiro
18018 activtrades
17875 admiral markets

¿Aún no eres usuario de Rankia?

Somos más de 200.000 usuarios

Regístrate y podrás:

  • Guardarte contenidos y usuarios
  • Participar en promociones especiales
  • Publicar mensajes en Foros y Opiniones
  • Participar en el Juego de Bolsa

Este sitio web usa cookies para analizar la navegación del usuario. Política de cookies.

Cerrar